NCT05644392

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours

An Open, Single-arm, Single-centre Clinical Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours That Have Failed at Least One Prior Systemic Therapy

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of Cadonilimab Injection in combination with Regorafenib in the treatment of intermediate to advanced biliary systemic tumours that has failed at least one prior systemic therapy

Detailed description

An open, single-arm, single-centre clinical study evaluating Cadonilimab Injection in combination with Regorafenib for the treatment of biliary systemic tumours that have failed at least one prior systemic therapy

Conditions

• Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy

Interventions

Type	Name	Description
DRUG	Cadonilimab Injection	Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
DRUG	Regorafenib	Regorafenib 80mg, po, orally once daily

Timeline

• Start date: 2022-11-25
• Primary completion: 2025-11-25
• Completion: 2025-11-25
• First posted: 2022-12-09
• Last updated: 2022-12-09

Locations

1 site across 1 country: China